back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2023-05-15 11:43 Tx date 2023-05-12 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Deferred Stock Unit
56 - Grant of rights
|
$44,998
+9,259 vol $4.86 each |
23,189 | |
| Filed 2023-03-21 21:24 Tx date 2023-03-17 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
$-155,200
-20,000 vol $7.76 each |
100,000 | |
| Filed 2022-05-16 10:03 Tx date 2022-05-13 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Deferred Stock Unit
56 - Grant of rights
|
$44,996
+8,620 vol $5.22 each |
13,930 | |
| Filed 2022-04-14 09:47 Tx date 2020-09-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,500
+414 vol $6.04 each |
46,128 | |
| Filed 2022-04-14 09:19 Tx date 2020-09-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,918
+414 vol $7.05 each |
||
| Filed 2022-04-13 12:19 Tx date 2022-04-08 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$532.00
+100 vol $5.32 each |
267,764 | |
| Filed 2022-04-13 12:18 Tx date 2022-04-08 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$267.00
+50 vol $5.34 each |
267,664 | |
| Filed 2022-04-13 12:14 Tx date 2021-01-13 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$89,590
+17,000 vol $5.27 each |
72,714 | |
| Filed 2021-01-13 16:05 Tx date 2021-01-13 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$52,699
+10,000 vol $5.27 each |
||
| Filed 2022-03-30 17:01 Tx date 2022-03-25 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
$-175,000
-20,000 vol $8.75 each |
120,000 | |
| Filed 2022-01-19 14:29 Tx date 2021-11-19 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$80,850
+15,000 vol $5.39 each |
260,614 | |
| Filed 2021-11-19 13:52 Tx date 2021-11-19 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$80,850
+15,000 vol $5.39 each |
||
| Filed 2021-11-19 18:02 Tx date 2021-11-16 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$34,130
+6,300 vol $5.42 each |
245,614 | |
| Filed 2021-11-19 18:01 Tx date 2021-11-16 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$19,459
+3,600 vol $5.41 each |
239,314 | |
| Filed 2021-11-19 17:48 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$52,375
+10,000 vol $5.24 each |
235,714 | |
| Filed 2021-11-19 17:48 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$132,187
+25,000 vol $5.29 each |
225,714 | |
| Filed 2021-11-19 17:48 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$132,187
+25,000 vol $5.29 each |
200,714 | |
| Filed 2021-11-19 17:47 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$70,157
+13,300 vol $5.28 each |
175,614 | |
| Filed 2021-11-19 17:46 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$52,250
+10,000 vol $5.22 each |
105,714 | |
| Filed 2021-11-19 17:45 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$52,375
+10,000 vol $5.24 each |
||
| Filed 2021-11-19 17:44 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$132,187
+25,000 vol $5.29 each |
||
| Filed 2021-11-19 17:44 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$132,187
+25,000 vol $5.29 each |
||
| Filed 2021-11-19 17:43 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$70,157
+13,300 vol $5.28 each |
||
| Filed 2021-11-19 17:42 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$52,250
+10,000 vol $5.22 each |
||
| Filed 2021-11-19 13:55 Tx date 2021-11-16 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$34,146
+6,300 vol $5.42 each |
||
| Filed 2021-11-19 13:55 Tx date 2021-11-16 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$34,146
+6,300 vol $5.42 each |
245,614 | |
| Filed 2021-11-19 13:55 Tx date 2021-11-16 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$19,476
+3,600 vol $5.41 each |
239,314 | |
| Filed 2021-11-19 13:55 Tx date 2021-11-16 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$19,476
+3,600 vol $5.41 each |
||
| Filed 2021-11-19 13:52 Tx date 2021-11-19 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$80,850
+15,000 vol $5.39 each |
260,614 | |
| Filed 2021-11-19 13:45 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$52,400
+10,000 vol $5.24 each |
235,714 | |
| Filed 2021-11-19 13:45 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$52,400
+10,000 vol $5.24 each |
||
| Filed 2021-11-19 13:45 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$132,250
+25,000 vol $5.29 each |
||
| Filed 2021-11-19 13:45 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$132,250
+25,000 vol $5.29 each |
225,714 | |
| Filed 2021-11-19 13:44 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$132,250
+25,000 vol $5.29 each |
||
| Filed 2021-11-19 13:44 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$132,250
+25,000 vol $5.29 each |
200,714 | |
| Filed 2021-11-19 13:44 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$528.00
+100 vol $5.28 each |
175,714 | |
| Filed 2021-11-19 13:44 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$70,224
+13,300 vol $5.28 each |
175,614 | |
| Filed 2021-11-19 13:44 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$70,224
+13,300 vol $5.28 each |
||
| Filed 2021-11-19 13:43 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$16,275
+3,100 vol $5.25 each |
162,314 | |
| Filed 2021-11-19 13:43 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$70,875
+13,500 vol $5.25 each |
159,214 | |
| Filed 2021-11-19 13:43 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$210,000
+40,000 vol $5.25 each |
145,714 | |
| Filed 2021-11-19 13:42 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$52,300
+10,000 vol $5.23 each |
105,714 | |
| Filed 2021-11-19 13:42 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$52,300
+10,000 vol $5.23 each |
||
| Filed 2021-11-19 13:41 Tx date 2021-11-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$52,000
+10,000 vol $5.20 each |
95,714 | |
| Filed 2021-08-18 14:20 Tx date 2021-08-18 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$109,800
+20,000 vol $5.49 each |
85,714 | |
| Filed 2021-05-24 15:35 Tx date 2021-05-18 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Deferred Stock Unit
56 - Grant of rights
|
$30,001
+5,310 vol $5.65 each |
5,310 | |
| Filed 2021-05-20 13:04 Tx date 2021-05-18 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Deferred Stock Unit
97 - Other
|
$30,001
+5,310 vol $5.65 each |
||
| Filed 2021-05-20 11:27 Tx date 2021-05-18 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Deferred Stock Unit
97 - Other
|
$30,001
+5,310 vol $5.65 each |
||
| Filed 2021-05-20 13:04 Tx date 2021-05-18 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Deferred Stock Unit
97 - Other
|
$30,001
+5,310 vol $5.65 each |
5,310 | |
| Filed 2021-05-20 13:04 Tx date 2014-02-28 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Deferred Stock Unit
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-05-20 13:03 Tx date 2014-06-02 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+20,000 vol |
20,000 | |
| Filed 2021-05-20 11:27 Tx date 2021-05-18 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Deferred Stock Unit
97 - Other
|
$30,001
+5,310 vol $5.65 each |
||
| Filed 2021-05-20 11:27 Tx date 2021-05-18 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Deferred Stock Unit
97 - Other
|
$30,001
+5,310 vol $5.65 each |
5,310 | |
| Filed 2021-05-20 11:26 Tx date 2014-02-28 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Deferred Stock Unit
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-05-20 11:26 Tx date 2014-02-28 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Deferred Stock Unit
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-05-20 11:26 Tx date 2014-06-02 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+20,000 vol |
||
| Filed 2021-05-20 11:26 Tx date 2014-06-02 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+20,000 vol |
20,000 | |
| Filed 2014-06-05 11:24 Tx date 2014-06-02 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+20,000 vol |
||
| Filed 2014-06-05 11:24 Tx date 2014-06-02 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+20,000 vol |
||
| Filed 2021-01-13 16:05 Tx date 2021-01-13 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$52,699
+10,000 vol $5.27 each |
65,714 | |
| Filed 2021-01-13 15:59 Tx date 2021-01-13 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$42,240
+8,000 vol $5.28 each |
55,714 | |
| Filed 2021-01-13 15:58 Tx date 2021-01-13 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$10,540
+2,000 vol $5.27 each |
47,714 | |
| Filed 2020-07-03 16:09 Tx date 2020-07-01 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+20,000 vol |
140,000 | |
| Filed 2019-09-18 11:17 Tx date 2019-09-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$2,498
+322 vol $7.76 each |
45,714 | |
| Filed 2019-07-15 09:28 Tx date 2019-07-11 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$150,300
+20,000 vol $7.51 each |
45,392 | |
| Filed 2019-05-15 15:28 Tx date 2019-05-14 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+20,000 vol |
120,000 | |
| Filed 2018-09-19 Tx date 2018-09-14 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$9,998
+1,209 vol $8.27 each |
||
| Filed 2018-09-19 Tx date 2018-09-17 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$9,998
+1,209 vol $8.27 each |
25,392 | |
| Filed 2018-09-17 Tx date 2018-09-14 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$9,998
+1,209 vol $8.27 each |
25,392 | |
| Filed 2018-05-16 Tx date 2018-05-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+20,000 vol |
100,000 | |
| Filed 2018-03-30 Tx date 2018-03-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$2,654
+333 vol $7.97 each |
24,183 | |
| Filed 2017-09-19 Tx date 2017-09-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$10,001
+1,147 vol $8.72 each |
23,850 | |
| Filed 2017-06-19 Tx date 2017-06-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$3,489
+355 vol $9.83 each |
22,703 | |
| Filed 2017-05-17 Tx date 2017-05-16 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+20,000 vol |
80,000 | |
| Filed 2016-04-04 Tx date 2016-03-30 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$9,999
+1,328 vol $7.53 each |
22,348 | |
| Filed 2015-12-18 Tx date 2015-12-16 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+20,000 vol |
60,000 | |
| Filed 2015-06-18 Tx date 2015-06-15 |
$GUD
Knight Therapeutics Inc. |
Lande, Robert Nathaniel
4 - Director of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$9,996
+1,420 vol $7.04 each |
21,020 |